Business
CareDx Celebrates 1 Million Organ Transplants and 100,000 Patient Milestone
One out of Ten Patients Served by CareDx Signals Broad Uptake of Company’s Non-Invasive Testing Services for Heart, Kidney, and Lung Transplant Patients
About this update from Caredx, Inc.
[{"type":"text","content":"\nOne out of Ten Patients Served by CareDx \n\nSignals Broad Uptake of Company’s Non-Invasive Testing Services for Heart, Kidney, and Lung Transplant Patients \n\n BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has served its 100,000th transplant patient, representing one out of ten patients transplanted in the U.S. This milestone demonstrates strong clinical adoption of molecular surveillance for transplant patients and showcases AlloMap® and AlloSure® as leading tools which are becoming firmly embedded in post-transplant patient care.\n\n“We celebrate the one millionth organ transplant patient in the U.S., a historical milestone reported by UNOS that represents countless saved lives. At CareDx we are extremely proud to have achieved our own milestone in serving 100,000 patients and one out of ten patients transplanted in the U.S.,” said Reg Seeto, CEO and President of CareDx. “This is a testament to our dedicated, 100 percent commitment to transplantation, and leading innovation with AlloSure and AlloMap.”\n\n“I’ve been a strong proponent of CareDx’s non-invasive testing services, and it is exciting to see their growing use in kidney transplantation,” said Tarek Alhamad, MD, Medical Director, Kidney Transplant Program, Barnes Jewish, Washington University. “It is truly remarkable to see how post-transplant care is evolving, and I am excited, along with other clinicians in the field, to see how the company’s imminent multimodal KidneyCare offering will help us better risk stratify allograft injury to proactively manage this condition, and potentially to reduce the need for biopsy.”\n\nCareDx AlloMap gene-expression profiling (GEP) was made commercially available in 2005 and AlloSure donor-derived cell-free DNA (dd-cfDNA) in 2017, both becoming the most widely used non-invasive tests of their kind to identify immune quiescence and the risk of graft injury in transplant recipients. AlloMap Heart is used in more than 90 percent of the nation’s heart transplant centers and in more than 1 in 2 newly transplanted patients.1 In 2020, CareDx launched HeartCare, which includes both AlloMap and AlloSure, and c...